Peptides DB
Research-centric peptide and protocol reference hub

Mazdutide (IBI362) record · updated 17h ago

Metabolic & appetiteInflammation & immuneGrade A · human clinicalResearch use only
All 30 studiesJump to the evidenceCompare
What is Mazdutide (IBI362) used for?

Mazdutide (IBI362) is an investigational dual GLP-1/glucagon receptor agonist studied for weight loss and type 2 diabetes, combining appetite suppression with increased energy expenditure.

How it works: GLP-1 / glucagon dual receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Mazdutide (IBI362) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Current
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 92 registered trials. It describes the research record, not a recommendation.

Identity
NameMazdutide (IBI362)
Chain length—
Molecular weight4,476 Da
FormulaC207H317N45O65
Structure typeNot established
ClassMetabolic
Research levelWell Studied
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 167312357. No verified residue count for this compound.

Pharmacology
MechanismGLP-1 / glucagon dual receptor agonist
RouteSubcutaneous injection
Half-life—
Time to peak—
DurationWeekly dosing (investigational)
Extraction confidence0.60
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 29, 2026. How this works →
Research stats
Total studies30
Human / animal / cellular9 / 7 / 3
Highest trial phasePhase 3
Years covered2023–2026
Latest study8d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

30 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Effectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report.
Finding20.6% reduction in body weight from 85.0 to 67.5 kg after 4 months.
Human2023Full text read0.80
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.
Finding-18.1% bodyweight change with 16 mg mazdutide at 32 weeks, n=51, p<0.0001.
Human2025Full text read0.80
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Finding-6.65 kg absolute body weight reduction, MD, moderate certainty.
review2023Full text read0.80
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Finding-6.65 kg absolute body weight reduction, MD, moderate certainty.
review2026Full text read0.80
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.
TakeawayNot reported in abstract.
review2026Title only0.10
External resistance modulates anodic biofilm architecture, electrochemical performance, and EET-related gene expression in Shewanella oneidensis MR-1 microbial fuel cells.
FindingMaximum power density of 130 mW m^-2 at 10 Ω.
In vitro2026Full text read0.90
Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients.
TakeawayNot reported in abstract.
review2026Title only0.10
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
FindingMedian progression-free survival 14.8 months (95% CI 11.2-16.6) for belzutifan-lenvatinib vs 10.7 months (95% CI 9.2-11.1) for cabozantinib; HR 0.70, one-sided p<0.0001.
Human2026Full text read0.90
Highly efficient production of β-caryophyllene in Saccharomyces cerevisiae using a novel synthase from Artemisia argyi.
FindingFinal β-caryophyllene titer of 35.4 g/L.
In vitro2026Full text read0.70
Intravenous lipid emulsion as rescue therapy in severe quetiapine overdose: A case report.
FindingGlasgow Coma Scale score improved to 14/15 within three hours.
Human2026Full text read0.70
Homocysteine, cysteine and methionine are associated with 90-day prognosis in intracerebral hemorrhage patients.
FindingAUC = 0.819
Human2026Full text read0.80
A Postprocessing Software Tool for 1H and 31P MRI Data Analysis.
FindingNot reported in abstract.
Animal2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Mazdutide (IBI362) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Mazdutide (IBI362) is discussed should be drawn from it.